David R. Epstein - 31 Mar 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Role: Director
Signature: /s/ Daniel S. Char, Attorney-in-Fact for David R. Epstein
Issuer symbol: EVLO on OTC
Transactions as of: 31 Mar 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Apr 2022, 16:05:38 UTC
Previous filing: 21 Mar 2022
Next filing: 22 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVLO	Common Stock	Options Exercise	$0	+2,052	+3.6%	$0.000000	59,157	31 Mar 2022	Direct	F1
transaction	EVLO	Common Stock	Options Exercise	$0	+2,874	+4.9%	$0.000000	62,031	31 Mar 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVLO	Restricted Stock Units	Options Exercise	$0	-2,052	-25%	$0.000000	6,158	31 Mar 2022	Common Stock	2,052	$0.000000	Direct	F2
transaction	EVLO	Restricted Stock Units	Options Exercise	$0	-2,874	-25%	$0.000000	8,620	31 Mar 2022	Common Stock	2,874	$0.000000	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Settlement of shares of Common Stock acquired upon the vesting of Restricted Stock Units previously granted to the reporting person.
F2	The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as chair of the board of directors of the issuer on such vesting dates.
F3	The Restricted Stock Units vest in 12 substantially equal monthly installments following the June 30, 2021 grant date, subject to the reporting person's continued service as a consultant to the issuer on such vesting dates.